update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
Published 1 year ago • 297 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
0:30
the impact of the emerald trial results based on duration of prior cdk4/6i in the metastatic setting
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
3:24
elacestrant shows improved pfs in patients with er-positive/her2-negative metastatic breast cancer
-
30:44
what's new for the patient with er /her2- mbc progressing on cdk 4/6 inhibitor therapy? expert pe...
-
3:20
roblox shadovis rpg | is darkseed armor set worth getting?
-
1:20:55
treatment of metastatic breast cancer
-
29:23
roblox | darkdivers beta | new armour.. mercy dive and en dive
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
2:37
elacestrant: a new weapon against advanced estrogen receptor-positive breast cancer
-
4:06
serena-2: camizestrant vs fulvestrant in post-menopausal women with advanced er /her- breast cancer
-
8:42
hr mbc: treatment after progression on cdk4/6 inhibition
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
1:41
dr. harold j. burstein on cdk4/cdk6 inhibitor abemaciclib in breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
11:22
treating er /her2-low metastatic breast cancer, 2l and beyond
-
1:01
what emerald phase iii trial could mean for breast cancer patients | virginia kaklamani, md
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
17:11
emerald lead to the elacestrant fda approval - oncbrothers in discussion w/ dr. virginia kaklamani
-
3:01
assessing elacestrant in ctdna-positive patients with er breast cancer